Moiz Bakhiet, MD, PhD, Professor and Chairman

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

Taking Research and Development to the Clinic: Issues for Physicians AAAS/FDLI Colloquium I Diagnostics and Diagnoses Paths to Personalized Medicine Howard.
Personalized Medicine in California Kathryn Lowell, Deputy Secretary for Life Sciences and Health Systems February, 2009.
¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
1. 2 Key Applications of Genetic and Genomic Testing (slide 1 of 2) Diagnosis of Disease: Whereby genetic or genomic tests are used to screen a patient.
Personalized Medicine Presentation by: Alex Wiki by: John and Lydia.
Evolving Nursing Roles for the Future: The Provision of Genetic and Genomic-Based Nursing Care Throughout the Health Care Continuum Dale Halsey Lea, MPH,
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Personalized Medicine
Dr. Dalal AL-Matrouk KBA Farwaniya Hospital
© 2014 Direct One Communications, Inc. All rights reserved. 1 New Insights into the Basic Mechanisms, Diagnosis, and Staging of Epilepsy Nicole Odom, MD.
Genetic Testing in Genomic Medicine Gail H. Vance M.D. Professor, Department of Medical & Molecular Genetics Indiana University School of Medicine.
OIE Global Conference on Veterinary Education and the Role of VSB Foz do Iguazu, Brazil – 4-6 December By Tjeerd Jorna – WVA Immediate Past President.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
The NIH Roadmap for Medical Research
University of Utah Department of Human Genetics Pharmacogenomics Louisa A. Stark, Ph.D. Director.
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Clinical Research Training
Building a Roadmap for Research IT John Brussolo Research IT Program Director September 6, 2012 © 2012 The Regents of the University of Michigan.
Introduction to Precision Medicine
Assay Development Breakout (red) Who was in the room? About half of attendees are active NGS users N=1 doing whole genome analyses Everyone else doing.
Precision Medicine A New Initiative. The Concept of Precision Medicine (PM) The prevention and treatment strategies that take individual variability into.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
1 SMEs – a priority for FP6 Barend Verachtert DG Research Unit B3 - Research and SMEs.
1 Genomics and the Human Condition Francis S. Collins, M.D., Ph.D. Dedication of Ken Olsen Science Center Gordon College September 27, 2008.
Developing medicines for the future and why it is challenging Angela Milne.
Personalized Medicine Dr. M. Jawad Hassan. Personalized Medicine Human Genome and SNPs What is personalized medicine? Pharmacogenetics Case study – warfarin.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 50 Gene Therapy and Pharmacogenomics.
EURORDIS Eurordis Position on Research Priorities for Rare Diseases.
Trend in diagnostic biochip development Eiichiro Ichiishi, M.D., Ph.D. Department of Internal Medicine International University of Health and Welfare Hospital.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
Medical Research and Education: Ethics Association of American Universities April 22, 2002 Francis S. Collins, M.D., Ph.D.
D4FF55A0-6B6F BF422A9BA9 Present by: Xiao Chen On December 7, 2015.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Challenges to drug design Did you know? Over 2 million people are hospitalized each year for adverse reactions to prescription drugs. Over 2 million.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Jan 2002 EDMA The central role of the Medical Laboratory in a World of Managed Health An EDMA presentation of the benefits of in vitro testing as a basis.
Technology of healthcare  BY: seemeka Johnson. Technology of healthcare Doctors now know that genetics play a part in possibly passing on diseases from.
Direct-to-Consumer Genetic Testing: Outputs from the EASAC-FEAM Working Group Martina Cornel VU University Medical Center, Amsterdam.
Doug Brutlag 2011 The impact of genomics on the future of medicine and health Muhammad Faisal 2015-Arid-3638 PhD(scholar) Biochemistry.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE
Biomarkers.
Bringing Genomics Home Your DNA: A Blueprint for Better Health
Semantic Web - caBIG Abstract: 21st century biomedical research is driven by massive amounts of data: automated technologies generate hundreds of.
Precision Medicine, Community Engagement, and Native Health
NCT: Gaining Medical Insights and Enhancing Care for Cancer Patients with SAP HANA® Organization National Center for Tumor Diseases (NCT) Heidelberg, part.
National Healthcare Science Week 2017
STRATEGIC ACADEMIC UNIT “PEOPLE & TECHNOLOGIES”
Big Data Analyses: The Cancer Moonshot
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Martina C. Cornel, J. M. Friedman, A. J. Goldenberg, K. J. Lister, K
The Many Careers of Pharmacy
Integrating Genetics & Genomics Education into Nursing Workforce
On Human Gene Editing: International Summit Statement
Community Pharmacy: Sharing Our Vision
Clinical Trials Medical Interventions
What Are Clinical Trials?
Integrating Genetics & Genomics Education into Nursing Workforce
From Bench to Clinical Applications: Money Talks
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
Pharmacogenomics Genes and Drugs.
FP6 Priority 1, Life Sciences Genomics and Biotechnology for Health
Session 3: Coverage and Reimbursement for Genetic Testing
Stratified Medicine: Will it be the Future of Medicine?
How Is Precision Medicine Transforming The Health Care Industry?
Presentation transcript:

Personalized medicine is the future sustainable knowledge for human wellbeing Moiz Bakhiet, MD, PhD, Professor and Chairman Dept. of Molecular Medicine Director of Al-Jawhara Center

The definition and scope of the term personalized medicine varies widely, ranging from the extremely broad to the very narrow. These examples have been selected to demonstrate the range of definitions that have been proposed: • “The use of new methods of molecular analysis to better manage a patient’s disease or predisposition to disease” – Personalized Medicine Coalition   • “Providing the right treatment to the right patient, at the right dose at the right time.” – European Union • “The tailoring of medical treatment to the individual characteristics of each patient.” – USA President’s Council of Advisors on Science and Technology • “Health care that is informed by each person’s unique clinical, genetic, and environmental information.” – American Medical Association • “A form of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease.” – National Cancer Institute, NIH

The establishment of the human genome and advances on proteomics has led to a rapidly advancing field of healthcare that is informed by each person's unique clinical, genetic, genomic makeup, and environmental information. These helped scientists and physicians to develop targeted diagnostics and therapeutic approaches to achieve more personalized management by identifying individual susceptibility to disease and response to particular treatment. Thus, personalized medicine can help in: elimination of redundant treatments decreasing side effects of drugs prevention and prediction of disease earlier intervention and reduction of health care costs

Pharmacogenomics Pharmacogenomics (PGx), the study of variations of DNA and RNA characteristics as related to drug response, is one of the most exciting areas of personalized medicine today.   Advances in PGx have opened new possibilities in drug discovery and development. PGx has allowed for more tailored treatment of a wide range of health problems, including cardiovascular disease, cancer, and HIV/AIDS. FDA approved several cancer drugs for use in patients whose tumors have specific genetic characteristics that are identified by a companion diagnostic test. Also, FDA approved a new therapy for use in certain cystic fibrosis, muscular and neuromuscular patients with a specific genetic mutation.

Challenges for Regulating Whole Genome Sequencing High-throughput genomic sequencing technologies are used extensively in research and have started to enter clinical practice.   Analysis: Whole genome sequencing (WGS), in which the entire human genome can be sequenced at a reasonable cost in a reasonable amount of time, is expected to bring transformative public health applications, yet WGS platforms are still evolving rapidly, and there are currently no agreed-upon approaches to analytically assess their performance. Validation: FDA approval or clearance of diagnostic tests generally requires demonstration of their analytical and clinical validity. However, in the case of WGS, sequence-based assays, and extensive gene panels, tests will involve the analysis of many alleles (3 billion base pairs in the case of WGS), so that demonstrating the validity of each and every variant may not be practical, since the significance of most of these variants is currently unknown. In addition, many variants detected by these methods are very rare, so that it is difficult to find enough patients to run a clinical trial to determine whether they are significant.

Towards Bahrain Genome Project: Building on International Experiences

Recommendations First: Second: The need for urgent and necessary launch of the National Genome Project which will contribute to the welfare and development of the society and particularly in the provision of appropriate and effective treatment especially in the early stages of life, in order to avoid the emergence of genetic and complexity diseases later in life.   Second: Providing effective treatment according to genetic makeup to reach positive results for the treatment of patients. Early intervention for treatment through an accurate understanding of the genome of the person and the common diseases in the community will in turn leads to saving time and costs of very expensive therapies. It will also reduce the burden on state budgets through the early detection of disease-related genome.

Third: Fourth: Fifth: Sixth: The development of professional competence in this important specialty. It is necessary to develop national occupational skills capable of building the National Genome Project, and the continuity of the work, and scientifically consolidate these competencies.   Fourth: National Genome Project requires cooperation and coordination between the relevant parties, especially between the official bodies to harmonize regulations and coordination within the National Genome Project. Fifth: Build and enhance the international cooperation with specialized international expertise and research centers, in building and sustaining the national genome project. Sixth: To create effective national participation and development of an integrated plan for awareness and education about the national genome project because of its paramount interest and importance to the health of the individual and society.

Vision   The Personalized medicine program vision is to be a uniquely, innovative and effective educational and research program to serve the health needs of the GCC citizens, and globally contribute to excellence in research and development, clinical services and health education. Mission  The mission of the Personalized Medicine Program is to acquire familiarity with genetic and genomic testing and gain theoretical and practical knowledge of personalized medicine and its role in making the treatment individualized as the disease.

Closing remarks: The era of personalized medicine has clearly arrived and that Personalized Medicine is the future sustainable knowledge for human wellbeing